Platford Giles Richard
President, IBU at TAK
- Sold, on record
- $532k
- Dollars the filings state
- Form 4 sales
- 1
- Latest Aug 10, 2026
- Form 144 notices
- 6
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- TAKTAKEDA PHARMACEUTICAL CO LTDPresident, IBU
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 144 notice TAKNoticeJul 10, 2023 2023
Filed to sell 24,394 shares ($378k)
Platford Giles Richard, President, Plasma-Derived Therapies Business Unit
No 10b5-1 planFirst sale on recordFiling
- 2 Form 144 notice TAKNoticeJul 10, 2024 +366 days
Filed to sell 20,721 shares ($273k)
Platford Giles Richard, President, Plasma-Derived Therapies Business Unit
No 10b5-1 planFirst sale on recordFiling
- 3 Form 144 notice TAKNoticeAug 22, 2024 +43 days
Filed to sell 19,073 shares ($285k)
Platford Giles Richard, President, Plasma-Derived Therapies Business Unit
No 10b5-1 planFirst sale on recordFiling
- 4 Form 144 notice TAKNoticeJul 9, 2025 +321 days
Filed to sell 28,552 shares ($440k)
Platford Giles Richard, President, Plasma-Derived Therapies Business Unit
No 10b5-1 planFirst sale on recordFiling
- 5 Form 144 notice TAKNoticeDec 4, 2025 +148 days
Filed to sell 58,421 shares ($836k)
Platford Giles Richard, President, Plasma-Derived Therapies Business Unit
No 10b5-1 planFirst sale on recordFiling
- 6 Form 144 notice TAKNoticeJul 13, 2026 +221 days
Filed to sell 33,696 shares ($564k)
Platford Giles Richard, President, International Business Unit
No 10b5-1 planFirst sale on recordFiling
- 7 Form 4 sale TAKNo planAug 10, 2026 +28 days
Sold 31,083 shares at $17.10 ($532k)
Platford Giles Richard, President, IBU
No 10b5-1 planSold 9% of holdings ($5.9M position)315,838 shares leftFirst sale on recordFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (7)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Aug 12, 2026 | TAK | President, IBU | Form 4 sale | 31,083 | $532k | 9.0% | No plan | SEC |
| Jul 13, 2026 | Jul 13, 2026 | TAK | President, International Business Unit | Form 144 notice | 33,696 | $564k | Notice | SEC | |
| Dec 4, 2025 | Dec 4, 2025 | TAK | President, Plasma-Derived Therapies Business Unit | Form 144 notice | 58,421 | $836k | Notice | SEC | |
| Jul 9, 2025 | Jul 9, 2025 | TAK | President, Plasma-Derived Therapies Business Unit | Form 144 notice | 28,552 | $440k | Notice | SEC | |
| Aug 22, 2024 | Aug 22, 2024 | TAK | President, Plasma-Derived Therapies Business Unit | Form 144 notice | 19,073 | $285k | Notice | SEC | |
| Jul 10, 2024 | Jul 10, 2024 | TAK | President, Plasma-Derived Therapies Business Unit | Form 144 notice | 20,721 | $273k | Notice | SEC | |
| Jul 10, 2023 | Jul 10, 2023 | TAK | President, Plasma-Derived Therapies Business Unit | Form 144 notice | 24,394 | $378k | Notice | SEC |